IRLAB Therapeutics Stock

IRLAB Therapeutics PP&E per Employee

The PP&E per Employee of IRLAB Therapeutics (IRLAB A.ST) as of Aug 10, 2026 is 445,136.36 SEK. In the previous year, PP&E per Employee was 303,272.73 SEK — a change of 46.78% (higher).

PP&E per Employee

445,136.36SEK

YoY

46.78%

Last updated:

PP&E per Employee of IRLAB Therapeutics is 2026 445,136.36 SEK. PP&E per Employee of IRLAB Therapeutics was 2025 303,272.73 SEK. It decreases by 46.78% higher compared to the previous year.
Access this data via the Eulerpool API

IRLAB Therapeutics Stock analysis

What does IRLAB Therapeutics do? IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry. IRLAB Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IRLAB Therapeutics stock

PP&E per Employee of IRLAB Therapeutics is 445,136.36 SEK in 2026.

PP&E per Employee of IRLAB Therapeutics changed from 303,272.73 SEK to 445,136.36 SEK, representing a 46.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee IRLAB Therapeutics since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's IRLAB Therapeutics historically and in real time.

Access this data via the Eulerpool API

Workforce — IRLAB Therapeutics

All Key Metrics — IRLAB Therapeutics